Browsing: GLP1GIPglucagon

Neurocrine Biosciences (Nasdaq: NBIX) has dosed the first participants in a Phase I first-in-human study of NBIP-1968, an internally discovered glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP)/glucagon receptor triple agonist for obesity. The study evaluates single ascending doses in adults across a range of body mass index categories, with safety and tolerability as the primary endpoint.…